Compare Carna Biosciences, Inc. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Operating profit has grown by an annual rate -215.58% of over the last 5 years
3
The company has declared negative results for the last 4 consecutive quarters
4
Risky - Negative EBITDA
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 7,986 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.53
-242.30%
9.24
Revenue and Profits:
Net Sales:
144 Million
(Quarterly Results - Sep 2025)
Net Profit:
-544 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2461.7%
0%
2461.7%
6 Months
2461.7%
0%
2461.7%
1 Year
1484.21%
0%
1484.21%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Carna Biosciences, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-29.23%
EBIT Growth (5y)
-215.58%
EBIT to Interest (avg)
-358.28
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.77
Sales to Capital Employed (avg)
0.37
Tax Ratio
0.13%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.14
EV to EBIT
-2.15
EV to EBITDA
-2.17
EV to Capital Employed
10.28
EV to Sales
7.73
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-479.32%
ROE (Latest)
-111.86%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
144.30
107.80
33.86%
Operating Profit (PBDIT) excl Other Income
-499.00
-555.60
10.19%
Interest
33.90
0.40
8,375.00%
Exceptional Items
-8.30
-0.20
-4,050.00%
Consolidate Net Profit
-544.00
-557.00
2.33%
Operating Profit Margin (Excl OI)
-3,457.40%
-5,155.90%
169.85%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 33.86% vs -24.77% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 2.33% vs -11.60% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
636.20
1,625.90
-60.87%
Operating Profit (PBDIT) excl Other Income
-2,044.90
-1,081.40
-89.10%
Interest
3.00
3.50
-14.29%
Exceptional Items
-93.20
-4.60
-1,926.09%
Consolidate Net Profit
-2,178.60
-1,152.90
-88.97%
Operating Profit Margin (Excl OI)
-3,263.10%
-687.00%
-257.61%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -60.87% vs 17.25% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -88.97% vs 14.57% in Dec 2023
About Carna Biosciences, Inc. 
Carna Biosciences, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






